Breaking News: Japan Suspends Recommendation of HPV Vaccines

June 16, 2013 By 1 Comment
Sanevax-square

By Norma Erickson 14 June 2013: Merck’s Gardasil and GlaxoSmithKline’s Cervarix took a hit as Japan’s  Ministry of Health, Labor and Welfare told local governments to suspend their previous recommendation for HPV vaccine administration to the country’s 12 to 16 year old girls. Mrs. Tomoko Saito, reporter for The Asahi Shimbun, emailed this front page news article to the SaneVax [...]

[Continue reading...]
Filed Under: HPV, Japan, SANE Vax Press Releases, Vaccine Adverse Events Tagged With: , ,

The Potential Significance of Aluminum/DNA Compounds in Gardasil on Health

May 9, 2013 By 3 Comments
Sanevax-square

By Norma Erickson Each dose of Gardasil contains 225mcg of aluminum-based adjuvant. Adjuvants are in vaccines to bring the antigen (the substance that stimulates the specific protective immune response) into contact with the immune system and influence the type of immunity produced, as well as the magnitude or duration of the immune response. In the [...]

[Continue reading...]
Filed Under: HPV, SANE Vax Press Releases, Vaccine Science, World News Tagged With: , ,

SaneVax Announces a New Gardasil Cervarix HPV Vaccine Survey

May 9, 2013 By 2 Comments
Gardasil Cervarix HPV Vaccine Survey

The SaneVax team is pleased to announce an opportunity for Gardasil and Cervarix HPV vaccine recipients and their families to help provide data regarding HPV vaccines’ risk versus benefit profile. The study is being conducted by an independent scientist, Dr. Chandler Marrs, and hosted on her website, Hormones Matter TM.  The purpose of this study [...]

[Continue reading...]
Filed Under: Cervarix, Gardasil / Silgard, SANE Vax Press Releases, World News Tagged With: , ,

SaneVax response to journal article promoting proposed nine-valent HPV vaccine

May 8, 2013 By Leave a Comment
IAC-logo

[Sanevax: The following letter to the editors of Infectious Agents and Cancer was submitted as a response to "Potential impact of a nine-valent vaccine in human papillomavirus related cancers," by Sylvia de Sanjosé, et al. After peer-review and approval, the letter was published in this month's edition of Infectious Agents and Cancer.] Dear Editors In Chief: The article entitled [...]

[Continue reading...]
Filed Under: HPV, SANE Vax in the News, SANE Vax Press Releases, United States, Vaccine Marketing Tagged With: ,

HPV Vaccines and Idiopathic Thrombocytopenic Purpura

April 27, 2013 By 11 Comments
Sanevax-square

By Norma Erickson Kirstie was only 12 years old when she was diagnosed with a rare disorder for which there is no known cure, Idiopathic Thrombocytopenic Purpura (ITP). This happened just a little over a month after her second injection of Gardasil. She will live with this disorder for the rest of her life. Unfortunately, [...]

[Continue reading...]
Filed Under: Cervarix, Gardasil / Silgard, Immune System, SANE Vax Press Releases, United States Tagged With: , ,

HPV Vaccine Safety: Has the CDC abandoned its mission?

April 2, 2013 By 5 Comments
Sanevax-square

By Norma Erickson What would happen if a vaccine turned out to cause more health problems than the disease it was meant to protect against? Are medical consumers watching this scenario unfold with HPV vaccines? The U.S. Center for Disease Control (CDC) states 90% of all HPV infections clear on their own with no symptoms [...]

[Continue reading...]
Filed Under: CDC, HPV, SANE Vax Press Releases, United States Tagged With: ,

HPV Vaccines: Betrayal of the Public Trust?

March 25, 2013 By 6 Comments
Sanevax-square

By Norma Erickson, President Last week, multiple news articles reported 44% of American parents refusing Gardasil or Cervarix for their children. Between 2008 and 2010, the percentage of parents concerned about the safety of these two vaccines nearly quadrupled. As of 2010, only 32% of eligible girls were vaccinated against HPV. What is wrong with [...]

[Continue reading...]
Filed Under: HPV, SANE Vax Press Releases, World News Tagged With: , ,

Gardasil: New Study Brings More Safety Questions to Light

March 13, 2013 By 3 Comments
Standard B-Conformation DNA

  By Norma Erickson, President Why were HPV-16 L1 DNA fragments detected in post mortem samples taken six months after Gardasil vaccination and not the other vaccine-relevant types? Dr. Sin Hang Lee, of Milford Hospital and Milford Molecular Laboratory, may have provided an answer in his most recently published paper entitled, Topological conformational changes of [...]

[Continue reading...]
Filed Under: Gardasil / Silgard, HPV Science, SANE Vax Press Releases, United States, Vaccine Science Tagged With: ,

SaneVax Press Release: Newly developed same-nested PCR method may help answer questions regarding HPV vaccine safety

January 8, 2013 By Leave a Comment
Sanevax-square

Troy, Montana (BusinessWire) – SaneVax Inc. announces the development of a new PCR methodology described in “Detection of human papillomavirus L1 gene DNA fragments in post-mortem blood and spleen after Gardasil® vaccination – A case report,” authored by Dr. Sin Hang Lee of Milford Hospital, Connecticut. This method may provide a way for concerned scientists [...]

[Continue reading...]
Filed Under: HPV, SANE Vax Press Releases, Science & Medicine, World News Tagged With: ,

Vaccines or Autism: Which came first?

December 3, 2012 By 1 Comment
Sanevax-square

By Norma Erickson, President There is no getting around it – Autism Spectrum Disorders have become a national health crisis of epic proportions in the United States. Autism has become everyone’s problem. If you are not yet personally affected, chances are you or a family member soon will be. The autism spectrum[1] is a complex [...]

[Continue reading...]
Filed Under: Autism, SANE Vax Press Releases, United States, Vaccines Tagged With: , ,